Table 1.
Baseline Characteristics of Study Population
| Reference Ranges | Total (n = 30) | Obese (n = 10) | Nonobese (n = 20) | P Value | |
|---|---|---|---|---|---|
| Age, y | 62.9 ± 12.1 | 65.3 ± 9.3 | 61.7 ± 13.4 | 0.454 | |
| Female, % | 21 (70.0) | 6 (60.0) | 15 (75.0) | 0.398 | |
| Postmenopausal, % | 18 (60.0) | 6 (60.0) | 12 (60.0) | 0.497 | |
| Years since menopause | 14.4 ± 7.4 | 12.5 ± 10.0 | 15.3 ± 6.0 | 0.458 | |
| Ethnicity, % | |||||
| White | 26 (86.7) | 10 (100.0) | 16 (80.0) | 0.435 | |
| Black | 1 (3.3) | 0 (0.0) | 1 (5.0) | ||
| Hispanic | 1 (3.3) | 0 (0.0) | 1 (5.0) | ||
| Asian | 2 (6.7) | 0 (0.0) | 2 (10.0) | ||
| Duration of PHPT, y | 6.46 ± 8.55 | 6.03 ± 7.30 | 6.67 ± 9.29 | 0.851 | |
| Meets surgical guidelines, % | 26 (86.7) | 10 (100.0) | 16 (80.0) | 0.129 | |
| History of fractures, % | 14 (46.7) | 4 (40.0) | 10 (50.0) | 0.605 | |
| Past use of bisphosphonates, % | 10 (33.3) | 2 (20.0) | 8 (40.0) | 0.273 | |
| Duration of use of bisphosphonates, y | 6.82 ± 3.74 | 5.50 ± 3.54 | 7.15 ± 3.95 | 0.608 | |
| BMI, kg/m2 | 27.3 ± 5.4 | 33.4 ± 2.5 | 24.3 ± 3.5 | 0.001 | |
| Weight, kg | 76.4 ± 17.0 | 92.0 ± 15.4 | 68.6 ± 11.7 | 0.001 | |
| Intact PTH, ng/mL | 14–66 | 90.6 ± 47.2 | 103.2 ± 62.0 | 84.6 ± 38.9 | 0.341 |
| Corrected calcium, mg/dL | 8.6–10.2 | 10.4 ± 0.6 | 10.4 ± 0.6 | 10.3 ± 0.6 | 0.695 |
| Albumin, g/dL | 3.5–5.5 | 4.6 ± 0.3 | 4.5 ± 0.2 | 4.6 ± 0.4 | 0.253 |
| 25OHD, ng/mL | 30–100 | 45.7 ± 14.7 | 48.6 ± 20.6 | 43.4 ± 8.6 | 0.552 |
| 1,25OHD, pg/mL | 16–65 | 65.7 ± 21.5 | 68.5 ± 15.3 | 64.2 ± 24.4 | 0.567 |
| Creatinine, μmol/L | 53–106 | 76.1 ± 19.2 | 74.3 ± 14.2 | 77.0 ± 21.6 | 0.720 |
| Estimated GFR, mL/min | >60 | 81.3 ± 17.5 | 81.8 ± 17.2 | 81.1 ± 18.1 | 0.921 |
| P1NP, μg/L | 19–83 | 66.2 ± 36.3 | 66.0 ± 30.2 | 66.3 ± 40.5 | 0.983 |
| C-telopeptide, ng/mL | 0.112–0.738 | 0.66 ± 0.35 | 0.75 ± 0.41 | 0.61 ± 0.32 | 0.348 |
| Phosphate, mg/dL | 2.5–4.5 | 2.83 ± 0.44 | 2.78 ± 0.46 | 2.86 ± 0.44 | 0.638 |
| Lumbar spine BMD, g/cm2 | 0.938 ± 0.16 | 0.936 ± 0.19 | 0.939 ± 0.15 | 0.963 | |
| Lumbar spine T-score | −1.12 ± 1.5 | −1.24 ± 1.8 | −1.07 ± 1.4 | 0.782 | |
| Lumbar spine Z-score | 0.25 ± 1.6 | 0.13 ± 1.9 | 0.31 ± 1.5 | 0.778 | |
| Femoral neck BMD, g/cm2 | 0.686 ± 0.11 | 0.702 ± 0.15 | 0.678 ± 0.09 | 0.655 | |
| Femoral neck T-score | −1.59 ± 0.9 | −1.47 ± 1.2 | −1.64 ± 0.7 | 0.646 | |
| Femoral neck Z-score | −0.27 ± 0.9 | −0.11 ± 1.2 | −0.35 ± 0.8 | 0.574 | |
| Total hip BMD, g/cm2 | 0.828 ± 0.13 | 0.847 ± 0.15 | 0.819 ± 0.12 | 0.579 | |
| Total hip T-score | −1.10 ± 0.9 | −0.98 ± 1.1 | −1.15 ± 0.8 | 0.633 | |
| Total hip Z-score | −0.11 ± 0.9 | −0.00 ± 1.1 | −0.17 ± 0.8 | 0.644 | |
| Distal radius BMD, g/cm2 | 0.636 ± 0.10 | 0.633 ± 0.11 | 0.638 ± 0.09 | 0.895 | |
| Distal radius T-score | −1.58 ± 1.5 | −1.89 ± 1.6 | −1.42 ± 0.5 | 0.447 | |
| Distal radius Z-score | −0.08 ± 1.4 | −0.39 ± 1.7 | 0.08 ± 1.3 | 0.414 |
Abbreviations: GFR, glomerular filtration rate; 1,25OHD, 1,25-dihydroxyvitamin D; 25OHD, 25-hydroxyvitamin D.